<DOC>
	<DOCNO>NCT00861705</DOCNO>
	<brief_summary>This randomized phase II trial study well paclitaxel without carboplatin and/or bevacizumab follow doxorubicin cyclophosphamide work treat patient breast cancer remove surgery . Drugs use chemotherapy , paclitaxel , carboplatin , doxorubicin , cyclophosphamide , work different way stop growth tumor cell , either kill cell stop dividing . Bevacizumab may stop growth tumor cell block blood flow tumor . Giving chemotherapy together bevacizumab surgery may make tumor small reduce amount normal tissue need remove .</brief_summary>
	<brief_title>Paclitaxel With Without Carboplatin and/or Bevacizumab Followed Doxorubicin Cyclophosphamide Treating Patients With Breast Cancer That Can Be Removed Surgery</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine whether add bevacizumab neoadjuvant weekly paclitaxel ( +/- carboplatin ) subsequent dose-dense doxorubicin cyclophosphamide ( ddAC ) significantly raise rate pathologic complete response ( pCR ) breast patient hormone receptor ( HR ) -poor/human epidermal growth factor receptor 2 ( HER2 ) ( - ) , resectable breast cancer . II . To determine whether add carboplatin every 3 week neoadjuvant weekly paclitaxel follow ddAC ( +/- bevacizumab ) significantly raise rate pCR breast patient HR-poor/HER2 ( - ) , resectable breast cancer . III . To determine whether add bevacizumab every 2 week neoadjuvant weekly paclitaxel ( +/- carboplatin ) subsequent ddAC significantly raise rate pCR breast patient basal-like breast cancer , define gene expression array . IV . To determine whether add carboplatin every 3 week neoadjuvant weekly paclitaxel follow ddAC ( +/- bevacizumab ) significantly raise rate pCR breast patient basal-like breast cancer , define gene expression array . SECONDARY OBJECTIVES : I . To determine pCR rate breast axilla , use American Joint Committee On Cancer ( AJCC ) TNM criterion ( version 6 ) , neoadjuvant weekly paclitaxel , without carboplatin , follow ddAC , without bevacizumab , give concurrently weekly paclitaxel ddAC , ( ) patient HR-poor/HER2 ( - ) , resectable breast cancer ( b ) subset patient basal-like breast cancer , define gene expression array . II . To assess whether interaction addition carboplatin bevacizumab neoadjuvant chemotherapy ( NAC ) weekly paclitaxel follow ddAC regard path pCR rate ( ) patient HR-poor/HER2 ( - ) , resectable breast cancer ( b ) subset patient basal-like breast cancer , define gene expression array . III . To assess toxicity control regimen ( weekly paclitaxel follow ddAC ) incremental toxicity associate addition carboplatin and/or bevacizumab patient population , include incidence febrile neutropenia , grade &gt; = 3 thrombocytopenia , grade &gt; = 2 neurotoxicity , grade &gt; = 3 hypertension , clinically significant bleed thrombotic ( include cardiovascular cerebrovascular ) event . IV . To determine recurrence-free survival ( RFS ) measure definitive surgery first event , time first failure ( TFF ) measure study entry first event . V. To determine overall survival ( OS ) , define time registration death cause . VI . To assess impact NAC weekly paclitaxel follow ddAC , without carboplatin and/or bevacizumab , axillary lymph node involvement surgery , particularly patient clinically histologically positive axillary lymph node prior initiation NAC . VII . To assess impact addition bevacizumab NAC incidence severity post-op complication , especially excessive bleeding , delay wound healing , thrombotic complication . VIII . To evaluate residual cancer burden ( RCB ) predictor RFS , TFF OS . IX . To determine correlation clinical , radiographic , pathologic response . TERTIARY OBJECTIVES : I . To assess whether impact addition carboplatin and/or bevacizumab NAC weekly paclitaxel follow ddAC achievement pathologic CRs patient HR-poor/HER2 ( - ) , resectable breast cancer influence molecular subtype , define gene expression array . II . To obtain blood , fresh frozen fix tumor tissue test specific hypotheses biomarker data exist evaluate biomarkers tissue , blood , serum may influence response toxicity weekly paclitaxel , ddAC , carboplatin , and/or bevacizumab . III . To obtain blood sample test specific hypothesis biomarker data exist evaluate biomarkers blood may influence response toxicity weekly paclitaxel , ddAC , carboplatin and/or bevacizumab . IV . To determine surgical practice pattern breast conservation sentinel lymphadenectomy patient undergo neoadjuvant chemotherapy . V. To examine practice pattern use sentinel lymphadenectomy ( pre-chemotherapy post-chemotherapy ) patient T2 T3 breast cancer . VI . To examine proportion patient present T2 T3 cancer undergo mastectomy despite cytoreduction adequate breast conservation . VII . To determine radiotherapy practice pattern post-mastectomy regional nodal irradiation patient undergo neoadjuvant chemotherapy . OUTLINE : Patients randomize 1 4 treatment arm . ARM I : Patients receive paclitaxel intravenously ( IV ) 60 minute weekly week 1-12 . Patients receive dose-dense doxorubicin hydrochloride IV 3-10 minute cyclophosphamide IV 5-60 minute ( ddAC ) week 13 , 15 , 17 , 19 . ARM II : Patients receive paclitaxel ddAC Arm I . Patients also receive bevacizumab IV 30-90 minute week 1 , 3 , 5 , 7 , 9 , 11 , 13 , 15 , 17 . ARM III : Patients receive paclitaxel ddAC Arm I . Patients also receive carboplatin IV 30 minute week 1 , 4 , 7 , 10 . ARM IV : Patients receive paclitaxel ddAC Arm I , bevacizumab Arm II , carboplatin Arm III . Patients arm undergo definitive surgery ( i.e. , modify radical mastectomy breast-conserving surgery appropriate management axilla ) 4-8 week completion neoadjuvant therapy . After completion study treatment , patient follow periodically 10 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Breast Neoplasms , Male</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Immunoglobulin G</mesh_term>
	<criteria>Invasive breast cancer , diagnose core needle incisional biopsy ( excisional biopsy permit ) The invasive tumor must hormone receptorpoor , define estrogen receptor ( ER ) progesterone receptor ( PgR ) negative stain present = &lt; 10 % invasive cancer cell immunohistochemistry ( IHC ) The invasive tumor must HER2negative , define IHC 01+ fluorescent situ hybridization ( FISH ) ratio ( HER2 gene copy/chromosome 17 ) &lt; 2.0 IHC 2+ Clinical stage IIIII invasive breast cancer intent perform surgical resection neoadjuvant therapy ; patient inflammatory breast cancer eligible ; stag rule metastatic disease recommend clinical stage III patient Patients multicentric bilateral disease eligible target lesion meet eligibility criterion Patient agree undergo pretreatment research biopsies No prior chemotherapy , hormone therapy , radiation therapy therapeutic intent cancer The target lesion breast must &gt; = 1 cm , clinically radiographically ; palpable radiographically measurable axillary adenopathy record serve measurable disease primary endpoint ; patient axillary disease ( identifiable tumor breast &gt; = 1 cm physical exam radiographic study ) eligible participate Patients history significant bleeding episode ( e.g. , hemoptysis , upper low gastrointestinal [ GI ] bleeding ) within 6 month registration eligible No serious nonhealing wound , skin ulcer bone fracture ; abdominal fistula , gastrointestinal perforation intraabdominal abscess within past 6 month ; major surgical procedure within 28 day prior randomization anticipation need major surgery course study The following consider major surgical procedure would prohibit 28 day prior , follow study randomization : obtaining require research needle biopsy ; placement radiopaque clip localize tumor tumor subsequent surgical resection ; placement port central venous access ; fine needle aspiration prominent suspicious axillary lymph node ; needle biopsy clinically radiographically detect lesion rule metastatic disease ; pretreatment sentinel lymph node sample No baseline neuropathy grade &gt; = 2 Zubrod performance status 01 Pregnant nursing woman eligible ; woman reproductive potential must negative pregnancy test baseline agree use effective , nonhormonal method contraception entire period treatment study Patients congestive heart failure eligible , patient myocardial infarction , unstable angina pectoris , arterial thrombotic event , stroke transient ischemia attack ( TIA ) within past 12 month , uncontrolled hypertension ( systolic blood pressure [ SBP ] &gt; 160 diastolic blood pressure [ DBP ] &gt; 90 ) , uncontrolled symptomatic arrhythmia , grade II great peripheral vascular disease Patients must pretreatment multi gate acquisition ( MUGA ) scan echocardiogram leave ventricular ejection fraction ( LVEF ) institutional low limit normal Granulocytes &gt; 1,000/mcl Platelets &gt; 100,000/mcl Total bilirubin = &lt; 1.5 x upper limit normal Calculated measure &gt; 30 ml/min Urine protein = &lt; 1+ urine protein creatinine ( UPC ) ratio &lt; 1 Patients discover &gt; = 2+ proteinuria baseline must undergo 24hour urine collection must demonstrate &lt; 1 g protein/24 hr , UPC ratio &lt; 1 allow participation study Serum alanine aminotransferase ( ALT ) = &lt; 2.5 x upper limit normal Serum beta human chorionic gonadotropin ( HCG ) negative ( woman child bear potential ) Prothrombin time ( PT ) /international normalize ratio ( INR ) = &lt; 1.5 x upper limit normal ( ULN ) Unless patient therapeutic dos warfarin ; , patient must INR = &lt; 3 stable dose warfarin , must active bleeding pathologic condition associate high risk bleeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>